Insud Pharma biotech subsidiary Mabxience has announced plans to add to its biosimilar production capacity as well as bolster its contract development and manufacturing business by investing in an expansion of its facility in León, Spain.
Mabxience Expands Biosimilar Capacity
Investment In Plant In León, Spain, Also Bolsters CDMO Business
Mabxience has announced plans to bolster its biosimilar manufacturing capacity as well as giving a boost to its CDMO business by expanding its facility in León, Spain.
More from Manufacturing
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
• By
Along with financial backing from the Canadian government, a fresh, decade-long partnership with Sandoz Canada will allow Delpharm to carry out modernization plans for its manufacturing facility in Boucherville, securing the local supply chain for sterile injectable medicines.
• By
Biocon Biologics is partnering with Civica to supply insulin aspart drug substance that will be used for final US manufacturing by Civica at its plant in Petersburg, Virginia.
• By
Viatris anticipates that half-a-billion dollars will disappear from its top line in 2025 on the back of the recent import alert for its oral solids facility in Indore, with much of the pain being caused by the firm’s failure to have its generic version of Revlimid exempt from the restrictions.